Top Stories

• 

  Smith Ventures, CommerceOne Buy Fintech Biz In $1.1B Deal

  By Jade Martinez-Pogue

  Fintech company Green Dot Corp. on Monday announced that it has agreed to be bought by Smith Ventures and Commer...(read more)

• 

  Google Ad Tech Judge 'Concerned' By DOJ's Breakup Timing

  By Bryan Koenig

  A Virginia federal judge expressed concern during oral arguments Friday that breaking up Google's advertising pl...(read more)

ADVERTISEMENT


• NCAA Votes To Keep Ban On Pro Sports Betting For Athletes

  By Elaine Briseño

  The NCAA Division I member schools, with a two-thirds vote, rescinded a rule change that would have allowed student-athletes and staff to bet on professional sports.

• NJ Strikes $49.5M Deal Over Pollution At Superfund Site

  By Carla Baranauckas

  The New Jersey Department of Environmental Protection has reached a $49.5 million settlement with Pechiney Plastics Packaging Inc., Bristol-Myers Squibb Co., Citigroup Inc. and other companies, resolving the state's long-running natural resource damages suit over extensive groundwater contamination across a 10,000-acre Superfund site, state officials announced Monday.

• Chancery Delays Settlement Ruling In Peloton Risk Suit

  By Jeff Montgomery

  Saying she wants to "get it right," Delaware's chancellor indicated on Monday she would rule before year's end on the Court of Chancery's part in a proposed multicourt settlement of derivative claims accusing Peloton's top officials of cashing in on inside information about an impending treadmill recall.

• Fla. Jury Awards $50M In DNA Case Involving Ex-Marvel CEO

  By David Minsky

  A Florida jury awarded more than $50 million to the wife of Marvel Entertainment's former CEO and his wife over the surreptitious collection of her DNA in an attempt to falsely link her to an anonymous hate letter campaign, finding a neighbor and an insurance company attorney conspired against the couple.

• Biotechs Go To Del. Chancery Over Cancer Drug Rights

  By Jarek Rutz

  A contract battle has broken out in the Delaware Chancery Court between two biotechs, each accusing the other of materially breaching a decade-old collaboration agreement governing rights to the cancer drug Jemperli.

• DOD Probes Sen. For Urging Troops To Defy Illegal Orders

  By Courtney Bublé

  The U.S. Department of Defense announced on Monday it is investigating Sen. Mark Kelly, D-Ariz., a retired Navy captain, for telling members of the military to not follow illegal orders.

• Ophthalmic Co. Hits Ch. 11 With $64M Debt, Eyeing Sale

  By Emily Lever

  Clearside Biomedical, a company developing treatments for eye diseases, has filed for Chapter 11 protection in Delaware bankruptcy court with $64 million in debt, saying it will attempt to sell its business during the case.

• American Signature Furniture Hits Ch. 11 With Sale Plan

  By Vince Sullivan

  Home furnishing retailer American Signature Furniture filed for Chapter 11 protection in Delaware on Saturday with a plan to close 33 of its stores and sell the remainder of its business to affiliates of its current owners.

• Ohio High School Board Opens Up NIL Deals For Athletes

  By Elaine Briseño

  The Ohio High School Athletic Association announced Monday that it will now allow student-athletes to earn money from contracts for their name, image and likeness, following an Ohio court's temporary pause on a bylaw that banned such deals.

• Justices Won't Hear Dispute Over So-Called Ch. 11 Double Dip

  By Rick Archer

  The U.S. Supreme Court on Monday said it will not hear arguments on whether a Texas bankruptcy judge allowed unsecured creditors to double-dip on their recoveries when he handed them control of bankrupt oil driller Sanchez Energy.

• Justices Won't Review Doctor's Conviction For Reusing Devices

  By Abigail Harrison

  The U.S. Supreme Court on Monday rejected a petition from a North Carolina physician seeking to revisit the Fourth Circuit's decision to back her conviction for healthcare fraud.

• Justices Refuse Drug Price-Fixing Class Action

  By Abigail Harrison

  The U.S. Supreme Court said Monday that it will not review the Fourth Circuit's decision to back the dismissal of a proposed class action accusing drugmakers of conspiring and inflating the price of a medication for Huntington's disease.